Patents by Inventor Yves Lobet

Yves Lobet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine composition
    Publication number: 20050281847
    Abstract: The present invention relates to the field of Gram-negative bacterial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to the field of useful Gram-negative bacterial outer membrane vesicle (or bleb) compositions comprising heterologously expressed Chlamydia antigens, and advantageous methods of rendering these compositions more effective and safer as a vaccine.
    Type: Application
    Filed: April 12, 2005
    Publication date: December 22, 2005
    Inventors: Francois-Xavier Berthet, Yves Lobet, Jan Poolman, Vincent Georges Verlant
  • Vaccine composition
    Publication number: 20040131625
    Abstract: The present invention relates to the field of Gram-negative bacterial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to the field of useful Gram-negative bacterial outer membrane vesicle (or bleb) compositions comprising heterologously expressed Chlamydia antigens, and advantageous methods of rendering these compositions more effective and safer as a vaccine.
    Type: Application
    Filed: February 3, 2004
    Publication date: July 8, 2004
    Inventors: Francois-Xavier Jacques Berthet, Yves Lobet, Jan Poolman, Vincent Georges Christian Louis Verlant
  • Vaccine composition
    Publication number: 20040126389
    Abstract: The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compositions comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compositions, and advantageous methods of use of such adjuvants.
    Type: Application
    Filed: September 15, 2003
    Publication date: July 1, 2004
    Inventors: Francois-Xavier Jacques Berthet, Wilfried L J Dalemans, Philippe Denoel, Guy Dequesne, Chriatiane Feron, Nathalie Garcon, Yves Lobet, Jan Poolman, Georges Thiry, Joelle Thonnard, Pierre Voet
  • Vaccine
    Publication number: 20040081662
    Abstract: The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.
    Type: Application
    Filed: October 8, 2003
    Publication date: April 29, 2004
    Inventors: Philippe Hermand, Craig A.J. Laferriere, Yves Lobet, Jan Poolman
  • Component for vaccine
    Publication number: 20040047880
    Abstract: The present invention relates to a component for a vaccine against menigococci, in particular peptides which mimic epitopes of meningococcal lipooligosaccharide, and to a vaccine comprising such a component.
    Type: Application
    Filed: September 10, 2003
    Publication date: March 11, 2004
    Inventors: Xavier Thomas De Bolle, Jean-Jacques Letesson, Yves Lobet, Pascal Yvon Mertens, Jan Poolman, Pierre Voet
  • Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 6676942
    Abstract: The invention related to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with know OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: January 13, 2004
    Assignees: SmithKline Beecham Biologicals (s.a.), Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Deutsches Krebs Forschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
  • Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 6113914
    Abstract: The invention relates to novel Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: September 5, 2000
    Assignee: Smithkline Beecham Biologicals (S.A.)
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
  • Vaccine
    Patent number: 6040427
    Abstract: The Bordetella pertussis toxin is genetically modified to express a toxin protein which is deficient in target-cell receptor binding and is used in a vaccine for protection against whooping cough.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: March 21, 2000
    Assignee: SmithKline Beecham Biologicals
    Inventors: Camille Locht, Yves Lobet
  • Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
    Patent number: 5942236
    Abstract: The invention relates to novet Borrelia, and OspA antigens derived therefrom. These antigens show little homology with known OspA's and are therefore useful as vaccine and diagnostic reagents. Multicomponent vaccines based on OspA's from different Borrelia groups are also disclosed.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: August 24, 1999
    Assignees: SmithKline Beecham Biologicals, Max-Planck-Gesellschaft zur Forderung der Wissenschafter e.V., Duetsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Yves Lobet, Markus Simon, Ulrich Schaible, Reinhard Wallich, Michael Kramer
  • Vaccine
    Patent number: 5786189
    Abstract: The Bordetella pertussis toxin is genetically modified to express a toxin protein which is deficient in target-cell receptor binding and is used in a vaccine for protection against whooping cough.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: July 28, 1998
    Assignee: SmithKline Beecham Biologicals (S.A.)
    Inventors: Camille Locht, Yves Lobet